Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 7/20 | 0.32 |
| ▸ | EED | O75530 | 6/20 | 0.32 |
| ▸ | RBBP4 | Q09028 | 6/20 | 0.32 |
| ▸ | SUZ12 | Q15022 | 6/20 | 0.32 |
| ▸ | AEBP2 | Q6ZN18 | 6/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27074906 | 0.85 | PDE10A (0.38) | JAK2LRRK2ADORA2AADORA2B | |
| SCHEMBL25933018 | 0.68 | GBA1 (0.51) | JAK2EZH2EEDRBBP4SUZ12 | |
| SCHEMBL27074823 | 0.68 | FGFR1 (0.39) | JAK2LRRK2ADORA2AADORA2B | |
| SCHEMBL20727202 | 0.68 | PDE4B (0.34) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL27074745 | 0.67 | PDE10A (0.37) | LRRK2 | |
| SCHEMBL27075031 | 0.67 | PDE6D (0.37) | LRRK2ADORA2AADORA2B | |
| SCHEMBL30729184 | 0.67 | PDE6D (0.37) | LRRK2ADORA2AADORA2B | |
| SCHEMBL30729195 | 0.65 | PDE6D (0.40) | LRRK2 | |
| SCHEMBL27075014 | 0.65 | PDE6D (0.40) | LRRK2 | |
| SCHEMBL17515852 | 0.63 | IDO1 (0.41) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | JAK2 3555/4885EZH2 3202/4885EED 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.